Ann: PAR Receives Allowance for Key US Patent, page-8

Whilst systematic benefits are brilliant outcomes for patients, my understanding is that it's still critical that we show "localised" benefit to OA of the knee for NDA.

This supporting patent data seems to highlight:

• our largest target cohort (women with OA) are benefiting the most via complete remission in knee BML
• unlike anti-NGF drugs (e.g. Tanezumab) that restrict blood supply with corresponding impact on bone tissue, iPPS is acting to enhance supply
• we're on track to become the first DMOAD (given dot point 1).